The role of inflammatory biomarkers in obstructive sleep apnea syndrome Source: International Congress 2018 – Sleep-disordered breathing: biomarkers and genetics and the role of hypoxia, insomnia, movement disorders and sleep quality Year: 2018
Selective activation of pro-inflammatory cytokines in obstructive sleep apnoea syndrome and impact of CPAP Source: Eur Respir J 2005; 26: Suppl. 49, 355s Year: 2005
Production of TNF-α, MMPs, and MCP-1 by monocytes and hypoxic stress in patients with obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2004; 24: Suppl. 48, 331s Year: 2004
5-lipoxygenase pathway: one of the mediators of early atherosclerosis in obstructive sleep apnea syndrome? Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Frequency of distribution of IL-1, IL-6 and TNFa gene polymorphism in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2006 - Metabolic control in obstructive sleep apnoea Year: 2006
Association between metabolic disturbances and inflammatory markers in obstructive sleep apnea (OSAS) patients Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea Year: 2008
The role of angiogenesis in obstructive sleep apnea (OSA) Source: Eur Respir J 2005; 26: Suppl. 49, 357s Year: 2005
The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004
Is obstructive sleep apnoea a comorbidity of COPD and is it involved in chronic systemic inflammatory syndrome? Source: Eur Respir J 2008; 31: 1381-1382 Year: 2008
Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation Source: Eur Respir J 2009; 33: 1195-1205 Year: 2009
Hypoxic stress in obstructive sleep apnea syndrome (OSAS) activates invasive ability of monocytes Source: Eur Respir J 2005; 26: Suppl. 49, 354s Year: 2005
The effect of theophylline and CPAP on cytokine release in patients with obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2006; 28: Suppl. 50, 216s Year: 2006
Local airway inflammation in obstructive sleep apnoea: the role of leptin Source: Eur Respir J 2006; 28: Suppl. 50, 645s Year: 2006
NKT cells in systemic inflammation in the obstructive sleep apnoea syndrome (OSAS) Source: International Congress 2015 – Mucosal immunology: what’s new in 2015 Year: 2015
Corticosteroids suppress in vitro tonsillar proliferation in children with obstructive sleep apnoea Source: Eur Respir J 2009; 33: 1077-1084 Year: 2009
Changes in inflammatory mediators as a result of intermittent hypoxia in obstructive sleep apnea syndrome Source: International Congress 2016 – Hypoxia, oxidative stress, and biomarkers in obstructive sleep apnoea Year: 2016
BNP or VEGF levels do not predict disease severity in obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005
Endothelin-1 levels, respiratory drive and hypercapnic response in obese patients with or without obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2010 - Lung disease and mountain sickness: the importance of ventilatory control Year: 2010
Signalling pathways in intermittent hypoxia and in obstructive sleep apnoea (OSA) Source: Annual Congress 2007 - Cardiovascular and metabolic consequences of obstructive sleep apnoea: early changes, biomarkers and impact of treatment Year: 2007
Increased upper airway cytokines and oxidative stress in severe obstructive sleep apnoea Source: Eur Respir J 2011; 37: 89-97 Year: 2011